error fb Gplus IN twitter down-arrow Email Phone Check-Mark padlock circle_arrow minus plus play_btn close Clipboard_Icon Shopping-Cart_Icon Speech_Bubble_Icon Stethoscope_Icon pharmacists menu left-arrow right-arrow facebook search cart

JDRF and Dexcom Present: #PowerofCGM

Dexcom is committed to working with partners like JDRF to ensure people with diabetes live better, safer and healthier lives until there is a cure. Please complete the form below to learn more about Dexcom CGM. For each qualified form completion, Dexcom will donate $100 to JDRF. #PowerofCGM

How CGM Works

Monitor glucose activity in real-time with a small sensor, transmitter and a compatible smart device or Dexcom Receiver.1 Get glucose readings every 5 minutes. Receive high/low glucose alerts and alarms and share your glucose data with up to 5 followers.2

Talk to others using Dexcom CGM

People are living their best life with help from CGM. Read their stories and join the conversation at TypeOneNation.org.

A1C reduction

CGM has proven to be the best outpatient glycemic management system for reducing A1C. People with type 1 diabetes experience an average A1C reduction of 1.3%.**3

Take the next step with Dexcom

Every day, more people are turning to continuous glucose monitors to manage their diabetes. If you want to learn more about CGM technology and are ready to start the process, provide a bit of information about yourself below.

Patient Information
Secure site HTTPS
Diabetes therapy
Secure site HTTPS

By submitting this form, you agree to the Dexcom Terms of Use and Privacy Policy, and agree that we may use information you provide us to communicate with you in accordance with those terms.

In addition, by checking the applicable box(es) below, you are agreeing to receive at the phone number set forth above, automated phone call and/or text communications, including pre-recorded and auto-dialed communications from or on behalf of Dexcom, Inc. ("Dexcom") concerning the marketing and sale of Dexcom’s products and services: you certify that a) you are the account holder and consent to enroll or have the account holder's consent to enroll and b) you are age 18 or older. Your service provider's airtime, message, and data rates may apply. Your consent is not required for purchase. You may opt out at any time by texting "STOP" in return to a text, calling Dexcom at 888-738-3646 or sending an email to privacy@dexcom.com.

In Collaboration With

 

 

 

** MDI patients with baseline A1C ≥ 8.5%

1 Click here for a list of compatible devices.
2 Following requires the Dexcom Follow App and Internet connectivity is required to access Dexcom Follow.
3 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The diamond randomized clinical trial. JAMA. 2017;317(4):371-378. doi:10.1001/jama.2016.19975.

 

SPECIAL INSTRUCTIONS: JDRF-DEXCOM DONATION PROGRAM: Dexcom will donate $100 to JDRF for every completed, qualified referral (first name, last name, address, phone, email, diabetes type, therapy type). “Qualified” is defined as a new patient, on intensive insulin therapy providing name, email, address, phone, city, zip, date of birth, diabetes type, diabetes therapy and insurance type. Qualified referrals to be counted by Dexcom, Inc.

 

TERMS & CONDITIONS: Eligibility and Restrictions: Valid for all patients other than the following who are not eligible for this Program. Patient leads submitted with any of the below criteria will not generate a donation to JDRF:

  • Individuals covered in any part by Medicaid, Medicare, Tricare, or any other federal or state health care programs (such as medical assistance programs);
  • Members of a Kaiser Permanente Health Plan, and any other health plan or insurance contract that prohibits this Program;
  • Residents of Massachusetts and South Dakota and any other state where prohibited by law; • Persons residing outside the United States and Puerto Rico;
  • Eligibility period is for leads submitted 2/1/18 – 3/31/18.
  • Offer not valid to existing Dexcom patients (ordered any Dexcom products within past year).
    By participating in this Program, the patient certifies that he or she will comply with the terms of the patient’s health insurance contract, including but not limited to those requiring notification to the payor of the existence or value of this Program. Limit 1 donation per patient. It is illegal to (or offer to) sell, purchase, or trade this offer. This promotion is not transferable and cannot be combined with any other programs, offers or discounts. Void where prohibited by law or taxed or restricted.

 

BRIEF SAFETY STATEMENT The Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System ("G5") is a glucose monitoring system indicated for the management of diabetes in persons age 2 years and older. The G5 is designed to replace fingerstick blood glucose testing for diabetes treatment decisions. The G5 also aids in the detection of episodes of hyperglycemia and hypoglycemia. The G5 is intended for single patient use and requires a prescription. CONTRAINDICATIONS Do not rely on the G5 CGM data if you have recently taken acetaminophen. Remove the G5 (sensor, transmitter, and receiver) before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or high-frequency electrical heat (diathermy) treatment. The G5 is MR Unsafe. Do not bring any portion of the G5 into the MRI environment. WARNING CGM-based diabetes treatment decisions are only approved with the G5, not previous generations of Dexcom CGM systems. Calibrate at least once every 12 hours using a fingerstick. If your G5 does not display a sensor glucose reading and an arrow, or if you are getting inaccurate or inconsistent readings, take a fingerstick. If your glucose readings and alerts do not match your symptoms or expectations, take a fingerstick to confirm. Failure to do so may lead to hyperglycemia or hypoglycemia. The G5 is not approved for use in pregnant women, persons on dialysis or critically ill persons. If a sensor breaks and no portion of it is visible above the skin, do not attempt to remove it. Seek professional medical help if you have infection or inflammation on or near the sensor insertion point. Report broken sensors to Dexcom Technical Support. Sensor placement is not approved for sites other than under the skin of the belly (ages 2 years and older) or upper buttocks (ages 2-17 years). To “share” data, you need an internet connection and a separate compatible smart device running the Dexcom Follow App. Contact Dexcom Toll Free at 877-339-2664 or www.dexcom.com for detailed indications for use and safety information.

 

© 2018 Dexcom Inc. All rights reserved. This product is covered by U.S. patent.